Group 1 - The core viewpoint of the news is that Weigao Blood Purification has shown a slight increase in stock price and has reported its financial performance, indicating growth in revenue and net profit [1][2]. - As of February 9, Weigao Blood Purification's stock price increased by 0.47%, with a trading volume of 36.10 million yuan. The financing buy-in amount was 5.05 million yuan, while the financing repayment was 7.37 million yuan, resulting in a net financing buy of -2.32 million yuan [1]. - The total balance of margin trading for Weigao Blood Purification as of February 9 is 120 million yuan, which accounts for 7.56% of its circulating market value [1]. Group 2 - As of September 30, the number of shareholders for Weigao Blood Purification is 24,800, a decrease of 20.95% from the previous period. The average circulating shares per person increased by 26.51% to 1,535 shares [2]. - For the period from January to September 2025, Weigao Blood Purification achieved an operating income of 2.736 billion yuan, representing a year-on-year growth of 3.45%. The net profit attributable to the parent company was 341 million yuan, with a year-on-year increase of 7.92% [2]. - Since its A-share listing, Weigao Blood Purification has distributed a total of 65.82 million yuan in dividends [3].
威高血净2月9日获融资买入504.67万元，融资余额1.20亿元